Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma

Abstract

Weekly docetaxel is very well tolerated as second-line therapy for NSCLC. The activity of this regimen appears to be comparable to the standard 3-week schedule. This regimen offers new opportunities for combination regimens, both as first- and second-line therapy for NSCLC.